BRAF and melanoma: EGFR is not expressed, in general, by melanoma cells, and in vitro studies concluded that EGFR expression is disadvantageous for BRAFV600E melanoma cells in the absence of BRAF or MEK inhibitor drugs, but it confers a selective advantage in the presence of these drugs.